
TABLE OF CONTENTS

Sr. No.	Titles	Page No.
Chapter 1: Introduction		
1.1	Introduction	2
1.2	Selection of Peptide	2
1.2.1	Current treatment approach and limitations	4
1.3	Dermal route for drug delivery	4
1.3.2	Carriers for protein/peptide delivery	5
1.3.2.1	Nano-structure lipid carriers (NLCs)	6
1.3.2.2	Liposomes	6
1.3.2.3	Lotion	6
1.4	Aims and Objective	6
1.5	Plan of Work	7
1.6	References	7
Chapter 2: Literature Review		
2.1	Introduction	14
2.1.1	Psoriasis	14
2.1.1.1	Pathogenesis of psoriasis	14
2.1.1.2	Types of psoriasis	16
2.1.1.3	Treatment of psoriasis	18
2.1.2	Eczema (Atopic Dermatitis)	19
2.1.2.1	Pathogenesis of eczema	19
2.1.2.2	Treatment of eczema	20
2.1.3	Antimicrobial peptides (AMPs)	21
2.1.3.1	Formulation strategies for AMPs	25
2.1.4	Dermal route for drug delivery for proteins and peptides	27
2.1.4.1	Factors affecting drug absorption across the skin	28
2.1.4.2	Skin penetration enhancement techniques	29
2.1.4.3	Conventional drug delivery systems	30
2.1.4.4	Lipid-based nanotechnology drug delivery systems	
2.1.4.5	Literature survey based on NLCs	32

2.1.4.6	Literature survey-based liposomes	36
2.2	References	40
Chapter 3: Analytical Method		
3.1	Introduction	53
3.2	List of Material and Instruments	53
3.3	HPLC method development	54
3.3.1	HPLC method development for Omiganan	54
3.3.1.1	Preparation of calibration plot of Omiganan	54
3.3.1.2	Validation of HPLC method for Omiganan	55
3.3.2	HPLC method development for DPK-060:	55
3.3.2.1	Preparation of calibration plot of DPK-060	56
3.3.2.2	Validation of HPLC method for DPK-060	56
3.4	Results and Discussion	57
3.4.1	HPLC method for Omiganan	57
3.4.2	Validation of HPLC method for Omiganan	59
3.4.3	HPLC method for DPK-060	61
3.4.4	Validation of HPLC method for DPK-060	63
3.5	Conclusion	64
3.6	References	64
Chapter 4: Preformulation study		
4.1	Introduction	66
4.2	Materials and Instruments	66
4.2.1	Materials	66
4.2.2	Instruments	67
4.3	Methodology	67
4.3.1	Melting point determination	67
4.3.2	Drug authentication by mass spectrometry	68
4.3.3	Screening of lipids/oils and surfactants based on solubility	68
4.3.4	Drug-excipients compatibility study by FT-IR	68
4.4	Result and Discussion	69
4.4.1	Melting point determination	69

4.4.2	Drug authentication by mass spectrometry	69
4.4.3	Screening of lipids/oils and surfactants based on solubility	71
4.4.4	Drug-excipients compatibility study by FT-IR	72
4.5	References	76
Chapter 5A) Formulation Development: Omiganan Nano-lipid Constructs		
5A.1	Introduction	78
5A.2	Materials and Instruments	78
5A.2.1	Materials	78
5A.2.2	Instruments	78
5A.3	Methodology	79
5A.3.1	Preparation of Omiganan loaded nano-lipid constructs	79
5A.3.2	QbD approach for the formulation development	79
5A.3.2.1	Optimization of Formulation by Box-Behnken Design (BBD)	80
5A.3.2.2	Particle size	81
5A.3.2.3	% Drug entrapment	82
5A.3.2.4	Preparation of gel for Omiganan and Omiganan nano-lipid constructs	82
5A.3.3	Characterization of optimized Omiganan NLCs and NLC gel	83
5A.3.3.1	Zeta potential	83
5A.3.3.2	Shape and surface morphology	83
5A.3.3.3	Viscosity of Omiganan gel	83
5A.3.3.4	Spreadability of Omiganan gel	84
5A.3.3.5	pH of Omiganan gel	84
5A.3.3.6	Assay of Omiganan gel	84
5A.4	Result and Discussion	85
5A.4.1	Preparation and optimization of Omiganan nano-lipid constructs	85
5A.4.1.1	Establishment of QTPP	85
5A.4.1.2	Formulation optimization by Box-Behnken Design	85
5A.4.1.3	Effect analysis of critical variables on responses	86

5A.4.1.3.1	Influence of investigated parameters on % Drug entrapment	86
5A.4.1.3.2	Influence of investigated parameters on Particle size	93
5A.4.1.3.3	Optimization using Desirability plot	100
5A.4.1.3.4	Establishment of Design Space	101
5A.4.1.3.5	Overlay Plot for predicted design space	101
5A.4.2	Characterization of optimized Omiganan nano-lipid constructs and Omiganan NLC gel	103
5A.4.2.1	Zeta potential	103
5A.4.2.2	Shape and surface morphology	103
5A.4.2.3	% Drug entrapment and % drug loading	104
5A.4.2.4	Viscosity of Omiganan NLC gel	105
5A.4.2.5	Spreadability of Omiganan NLC gel	105
5A.4.2.6	pH of Omiganan NLC gel	105
5A.4.2.7	Assay of Omiganan gel	105
5A.5	References	105
Chapter 5B) Formulation Development: Omiganan Liposomes		
5B.1	Introduction	110
5B.2	Materials and Instruments	110
5B.2.1	Materials	110
5B.2.2	Instruments	110
5B.3	Methodology	111
5B.3.1	Preparation of Omiganan loaded liposomes	111
5B.3.2	QbD approach for the formulation development	111
5B.3.2.1	Optimization of Formulation by BBD	112
5B.3.2.2	Vesicle size	113
5B.3.2.3	% Drug entrapment	113
5B.3.2.4	Preparation of gel for Omiganan and Omiganan liposomes	114
5B.3.3	Characterization of optimized Omiganan liposomes and liposomal gel	114
5B.3.3.1	Zeta potential	114
5B.3.3.2	Shape and surface morphology	114

5B.3.3.3	Viscosity of Omiganan liposomal gel	115
5B.3.3.4	Spreadability of Omiganan liposomal gel	115
5B.3.3.5	pH of Omiganan liposomal gel	115
5B.3.3.6	Assay of Omiganan gel	115
5B.4	Result and Discussion	116
5B.4.1	Preparation and optimization of Omiganan liposomes	116
5B.4.1.1	Establishment of QTPP	116
5B.4.1.2	Formulation optimization by Box-Behnken Design	116
5B.4.1.3	Effect analysis of critical variables on responses	118
5B4.1.3.1	Influence of investigated parameters on % Drug entrapment	118
5B.4.1.3.2	Influence of investigated parameters on vesicle size	125
5B.4.1.3.3	Optimization using Desirability plot	131
5B.4.1.3.4	Establishment of Design Space	133
5B.4.1.3.5	Overlay Plot for predicted design space	133
5B.4.2	Characterization of optimized Omiganan liposomes and Omiganan liposomal gel	135
5B.4.2.1	Zeta potential	135
5B.4.2.2	Shape and surface morphology	135
5B.4.2.3	% Drug entrapment and % drug loading	136
5B.4.2.4	Viscosity of Omiganan liposomal gel	136
5B.4.2.5	Spreadability of Omiganan liposomal gel	137
5B.4.2.6	pH of Omiganan liposomal gel	137
5B.4.2.7	Assay of Omiganan gel	137
5B.5	References	137
Chapter 5C) Formulation Development: Omiganan lotion		
5C.1	Introduction	140
5C.2	Materials and Instruments	140
5C.2.1	Materials	140

5C.2.2	Instruments	141
5C.3	Methods	141
5C.3.1	Preparation of Omiganan lotion	141
5C.3.2	Characterization of Omiganan lotion	142
5C.3.2.1	Organoleptic characteristics	142
5C.3.2.2	Assay	142
5C.3.2.3	Viscosity	142
5C.3.2.4	Spreadability	143
5C.3.2.5	pH	143
5C.3.2.6	Thermodynamic Stability	143
5C.4	Results and Discussion	144
5C.4.2.1	Organoleptic characteristics	144
5C.4.2.2	Assay	144
5C.4.2.3	Viscosity	144
5C.4.2.4	Spreadability	144
5C.4.2.5	pH	144
5C.4.2.6	Thermodynamic Stability	144
5C.5	References	145
Chapter 6A) Formulation Development: DPK-060 Nano-lipid Constructs		
6A.1	Introduction	147
6A.2	Materials and Instruments	147
6A.2.1	Materials	147
6A.2.2	Instruments	147
6A.3	Methodology	148
6A.3.1	Preparation of DPK-060 loaded nano-lipid constructs	148
6A.3.2	QbD approach for the formulation development	148
6A.3.2.1	Optimization of Formulation by Box-Behnken Design (BBD)	149
6A.3.2.2	Particle size	150
6A.3.2.3	% Drug entrapment	150

6A.3.2.4	Preparation of gel for DPK-060 and DPK-060 nano-lipid constructs	151
6A.3.3	Characterization of optimized DPK-060 NLCs and NLC gel	151
6A.3.3.1	Zeta potential	151
6A.3.3.2	Shape and surface morphology	151
6A.3.3.3	Viscosity of DPK-060 gel	152
6A.3.3.4	Spreadability of DPK-060 gel	152
6A.3.3.5	pH of DPK-060 gel	152
6A.3.3.6	Assay of DPK-060 gel	152
6A.4	Result and Discussion	153
6A.4.1	Preparation and optimization of DPK-060 nano-lipid constructs	153
6A.4.1.1	Establishment of QTPP	153
6A.4.1.2	Formulation optimization by Box-Behnken Design	153
6A.4.1.3	Effect analysis of critical variables on responses	155
6A.4.1.3.1	Influence of investigated parameters on % Drug entrapment	155
6A.4.1.3.2	Influence of investigated parameters on Particle size	161
6A.4.1.3.3	Optimization using Desirability plot	168
6A.4.1.3.4	Establishment of Design Space	170
6A.4.1.3.5	Overlay Plot for predicted design space	170
6A.4.2	Characterization of optimized DPK-060 NLCs and DPK-060 NLC gel	171
6A.4.2.1	Zeta potential	171
6A.4.2.2	Shape and surface morphology	171
6A.4.2.3	% Drug entrapment and % drug loading	173
6A.4.2.4	Viscosity of DPK-060 NLC gel	173
6A.4.2.5	Spreadability of DPK-060 NLC gel	173

6A.4.2.6	pH of DPK-060 NLC gel	173
6A.4.2.7	Assay of DPK-060 gel	173
6A.5	References	173
Chapter 6B) Formulation Development: DPK-060 Lotion		
6B.1	Introduction	177
6B.2	Materials and Instruments	177
6B.2.1	Materials	177
6B.2.2	Instruments	178
6B.3	Methods	178
6B.3.1	Preparation of DPK-060 lotion	178
6B.3.2	Characterization of DPK-060 lotion	179
6B.3.2.1	Organoleptic characteristics	179
6B.3.2.2	Assay	179
6B.3.2.3	Viscosity	179
6B.3.2.4	Spreadability	180
6B.3.2.5	pH	180
6B.3.2.6	Thermodynamic Stability	180
6B.4	Results and Discussion	181
6B.4.2.1	Organoleptic characteristics	181
6B.4.2.2	Assay	181
6B.4.2.3	Viscosity	181
6B.4.2.4	Spreadability	181
6B.4.2.5	pH	181
6B.4.2.6	Thermodynamic Stability	181
6B.5	References	182
Chapter 7 <i>In-vitro</i> and <i>ex-vivo</i> studies		
7.1	Introduction	184
7.2	Materials and Instruments	184
7.3	Methods	185

7.3.1	<i>In-vitro</i> drug release study	185
7.3.2	<i>In-vitro</i> cytotoxicity and cellular uptake studies	186
7.3.2.1	Cell culture handling and sub-culturing protocol	186
7.3.2.2	MTT assay	186
7.3.2.3	Cellular uptake studies	187
7.3.3	<i>In-vitro</i> determination of minimum inhibitory concentration (MIC)	188
7.3.4	<i>In-vitro</i> hemocompatibility studies	188
7.3.5	Protease sensitivity assay	188
7.3.6	<i>Ex-vivo</i> permeation and skin retention studies	189
7.3.7	<i>Ex-vivo</i> fluorescence microscopic study	189
7.4	Results and Discussion	190
7.4.1	<i>In-vitro</i> drug release study	190
7.4.2	<i>In-vitro</i> cytotoxicity and cellular uptake studies	193
7.4.2.1	MTT assay	196
7.4.2.2	Cellular uptake studies	196
7.4.3	<i>In-vitro</i> determination of minimum inhibitory concentration (MIC)	198
7.4.4	<i>In-vitro</i> hemocompatibility studies	199
7.4.5	Protease sensitivity assay	200
7.4.6	<i>Ex-vivo</i> permeation and skin retention studies	202
7.4.7	<i>Ex-vivo</i> fluorescence microscopic study	204
7.5	References	207
Chapter 8 <i>In-vivo</i> studies		
8.1	Animals	211
8.2	Pharmacodynamic Study	211
8.2.1	Imiquimod induced psoriatic animal model	211
8.2.1.1	Psoriatic scoring	212
8.2.1.2	Spleen and body weight	212

8.2.1.3	Histopathology	212
8.2.1.4	Cytokines levels in serum	213
8.2.2	Ovalbumin induced animal model for eczema/atopic dermatitis (AD)	213
8.2.2.1	Histopathology	214
8.2.2.2	Cytokines levels in serum	215
8.2.3	Statistical analysis	215
8.3	Results and Discussion	216
8.3.1	Imiquimod (IMQ) induced psoriatic animal model	216
8.3.1.1	Psoriatic scoring	217
8.3.1.2	Spleen and body weight	220
8.3.1.3	Histopathology	221
8.3.1.4	Cytokines levels in serum	223
8.3.2	Ovalbumin induced animal model for eczema/atopic dermatitis	223
8.3.2.1	Histopathology	225
8.3.2.2	Cytokines levels in serum	226
8.4	References	228
Chapter 9 Stability Study		
9.1	Introduction	231
9.2	Short term stability study of Omiganan and DPK 060 loaded formulations	231
9.3	Results and Discussion	232
9.4	References	233
Chapter 10 Summary and Conclusion		
10.1	Summary	235
10.2	Conclusion	244